Protective antigens from El Tor vibrios. 1. The preparation and properties of a purified protective antigen from an El Tor vibrio (Ogawa subtype)
- PMID: 5294306
- PMCID: PMC2555277
Protective antigens from El Tor vibrios. 1. The preparation and properties of a purified protective antigen from an El Tor vibrio (Ogawa subtype)
Abstract
A biochemically and immunologically homogeneous antigenic fraction having the properties of a lipopolysaccharide has been isolated from the culture supernatant of an El Tor vibrio (Ogawa subtype). This antigen was very specifically protective for mice challenged with Ogawa strains of either El Tor vibrios or Vibrio cholerae. Rabbit antisera prepared against the antigen were passively protective for mice and highly vibriocidal but had little agglutinating activity. However, the antigen was able specifically to absorb agglutinins, as well as mouse-protective and vibriocidal antibody from serum prepared against whole bacterial cells. The specific protective activity of this lipopolysaccharide was much greater than that of vaccines made from whole bacterial cells, and its toxicity in animals was about equivalent to that of whole cells. The relationship of activity to toxicity therefore represented an improvement over the vaccines that were studied.
Similar articles
-
Protective antigens from El Tor vibrios. 2. Responses in animals and man to a partially purified Ogawa lipopolysaccharide antigen.Bull World Health Organ. 1965;32(6):823-31. Bull World Health Organ. 1965. PMID: 5294307 Free PMC article.
-
Protective activity of cholera vaccines against E1 Tor cholera vibrios.Bull World Health Organ. 1963;28(3):379-83. Bull World Health Organ. 1963. PMID: 13943861 Free PMC article.
-
Interaction of Vibrio cholerae and Vibrio El Tor.Bull World Health Organ. 1966;34(3):371-8. Bull World Health Organ. 1966. PMID: 5296397 Free PMC article.
-
Laboratory studies on the El Tor vibrio.Bull World Health Organ. 1963;28(3):311-25. Bull World Health Organ. 1963. PMID: 13986981 Free PMC article.
-
A review of the current status of enteric vaccines.P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.
Cited by
-
Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field.Bull World Health Organ. 1968;38(3):359-72. Bull World Health Organ. 1968. PMID: 5302329 Free PMC article. Clinical Trial.
-
Characterization and distribution of the hemagglutinins produced by Vibrio cholerae.Infect Immun. 1982 Apr;36(1):209-14. doi: 10.1128/iai.36.1.209-214.1982. Infect Immun. 1982. PMID: 7076294 Free PMC article.
-
Immunity to cholera: relation of fraction II of type 2 cholera toxin to vibriocidal antibody.J Bacteriol. 1969 May;98(2):467-74. doi: 10.1128/jb.98.2.467-474.1969. J Bacteriol. 1969. PMID: 4977478 Free PMC article.
-
Immunochemical studies on lipopolysaccharide from agglutinable and non-agglutinable vibrios.Appl Microbiol. 1974 Apr;27(4):634-9. doi: 10.1128/am.27.4.634-639.1974. Appl Microbiol. 1974. PMID: 4207760 Free PMC article.
-
Protective antigens from El Tor vibrios. 2. Responses in animals and man to a partially purified Ogawa lipopolysaccharide antigen.Bull World Health Organ. 1965;32(6):823-31. Bull World Health Organ. 1965. PMID: 5294307 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources